Paul Gougis
Overview
Explore the profile of Paul Gougis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mamou E, Gougis P, Abbar B, Spano J, Morardet L, Vozy A
Head Neck
. 2025 Mar;
PMID: 40067281
Purpose: Hypercalcemia is the most common metabolic disorder in cancer, affecting 10%-20% of patients with advanced malignancies, including squamous cell carcinoma of the head and neck (HNSCC), though its prognostic...
2.
Dumas E, Jochum F, Coussy F, Hamy A, Majdling A, Houzard S, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401131.
PMID: 40043224
Purpose: Young age is associated with increased risk of recurrence in hormone receptor (HR)-positive early-stage breast cancer (eBC). Lack of adherence to endocrine therapy (ET) is a potential reason for...
3.
Jochum F, Doll M, Hamy A, Donval L, Gougis P, Dumas E, et al.
EClinicalMedicine
. 2025 Jan;
80:103053.
PMID: 39867969
Background: Randomized clinical trials (RCTs) are fundamental to evidence-based medicine, but their real-world impact on clinical practice often remains unmonitored. Leveraging large-scale real-world data can enable systematic monitoring of RCT...
4.
Santonja C, Gougis P, Dumas E, Rolland Debord C, Merle P, Belliere A, et al.
Transl Lung Cancer Res
. 2025 Jan;
13(12):3603-3615.
PMID: 39830773
Background: Oligoprogression (OP) is common in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs). This study aims to assess the benefit and the safety...
5.
Laas E, Dumas E, Hamy A, Gaillard T, Gougis P, Reyal F, et al.
Eur J Surg Oncol
. 2024 Nov;
51(1):109373.
PMID: 39549387
Background: Suboptimal treatment delays is known to impact prognosis of patients with cancer but optimal timing in specific subgroups remains poorly studied. This study aimed to analyze treatment delays in...
6.
Jochum F, Hamy A, Gougis P, Dumas E, Grandal B, Sauzey M, et al.
Br J Surg
. 2024 Aug;
111(8).
PMID: 39150046
Background: The main objective of this study was to undertake an exhaustive investigation of sex-related differences in cancer surgery. Methods: This observational study used data from the French national health...
7.
Jochum F, Dumas E, Gougis P, Hamy A, Querleu D, Lecointre L, et al.
Am J Obstet Gynecol
. 2024 Aug;
232(2):194.e1-194.e11.
PMID: 39111517
Background: The effect of primary cytoreductive surgery vs interval cytoreductive surgery on International Federation of Gynecology and Obstetrics stage IV ovarian cancer outcomes remains uncertain and may vary depending on...
8.
Combarel D, Geraud A, Gougis P
Clin Pharmacol Ther
. 2024 Jul;
116(3):506-507.
PMID: 38970295
No abstract available.
9.
Giacchetti S, Laas E, Bachelot T, Lemonnier J, Andre F, Cameron D, et al.
EBioMedicine
. 2024 May;
104:105141.
PMID: 38718683
Background: Circadian rhythms regulate cellular physiology and could influence the efficacy of endocrine therapy (ET) in breast cancer (BC). We prospectively tested this hypothesis within the UNIRAD adjuvant phase III...
10.
Gougis P, Hamy A, Jochum F, Bihan K, Carbonnel M, Salem J, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e245625.
PMID: 38630478
Importance: With the widespread use of immune checkpoint inhibitors (ICIs), concerns about their pregnancy outcomes through maternal exposure have emerged, and clinical comparative data are lacking. Objective: To assess the...